Cargando…

细胞周期检测点激酶与肺癌耐药研究进展

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105604/
https://www.ncbi.nlm.nih.gov/pubmed/33910274
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09
_version_ 1783689634562179072
collection PubMed
description Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer.
format Online
Article
Text
id pubmed-8105604
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-81056042021-05-24 细胞周期检测点激酶与肺癌耐药研究进展 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer. 中国肺癌杂志编辑部 2021-04-20 /pmc/articles/PMC8105604/ /pubmed/33910274 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
细胞周期检测点激酶与肺癌耐药研究进展
title 细胞周期检测点激酶与肺癌耐药研究进展
title_full 细胞周期检测点激酶与肺癌耐药研究进展
title_fullStr 细胞周期检测点激酶与肺癌耐药研究进展
title_full_unstemmed 细胞周期检测点激酶与肺癌耐药研究进展
title_short 细胞周期检测点激酶与肺癌耐药研究进展
title_sort 细胞周期检测点激酶与肺癌耐药研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105604/
https://www.ncbi.nlm.nih.gov/pubmed/33910274
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09
work_keys_str_mv AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn
AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn
AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn